We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Senseonics Holdings Inc | AMEX:SENS | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.0051 | -0.98% | 0.513 | 0.5264 | 0.5011 | 0.518 | 1,502,650 | 00:24:12 |
PARSIPPANY, N.J., Feb. 14, 2022 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, announces that its partner Senseonics Holdings, Inc. (NYSE American: SENS) has received approval from the U.S. Food and Drug Administration (FDA) for the next-generation Eversense® E3 Continuous Glucose Monitoring (CGM) System. Ascensia plans to make the Eversense E3 sensor, which can be used for up to 6 months, available to patients in the U.S. during the second quarter of 2022.
Robert Schumm, President at Ascensia Diabetes Care, said, "As the world's first and only long-term CGM System, Eversense is truly innovative and the prospect of using a single sensor for 6 months is a huge step forward for people with diabetes. Ensuring that as many people as possible have access to Eversense E3 is key for us and we'll be introducing a program to help users experience Eversense affordably as we work closely with payers on coverage. We look forward to rolling out this next-generation system through our dedicated CGM commercial team in the U.S. in the coming months, as we strive to improve the lives of people with diabetes everywhere."
Developed by Senseonics and brought to people with diabetes by Ascensia, the newly approved Eversense E3 CGM System, which includes a sacrificial boronic acid (SBA) design modification to enhance sensor survival, offers patients:
"This next generation system delivers on the patient's desire for a CGM sensor that is both long-lasting and highly accurate," said Elaine Anderson, Head of Eversense CGM Business Unit at Ascensia Diabetes Care. "Its unique features and benefits offer people with diabetes unparalleled flexibility, convenience and accuracy. Our partner Senseonics has designed Eversense E3 with the user in mind and we are excited to bring the system to people in the U.S. in the second quarter."
To be among the first to know when Eversense E3 is commercially available, patients who are interested in getting started with Eversense now can sign up at www.eversensediabetes.com/get-started-today. Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense CGM System can sign up at www.ascensiadiabetes.com/eversense/become-a-provider/register/. Alternatively, contact 844-SENSE4U (844-736-7348) to learn more about the first and only long-term implantable CGM system.
* There is no glucose data generated when the transmitter is removed.
1 Garg S. et al. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics 2021; 24(2): 1-9.DOI: 10.1089/dia.2021.0182
View original content:https://www.prnewswire.com/news-releases/ascensia-diabetes-care-announces-fda-approval-of-the-eversense-e3-continuous-glucose-monitoring-system-for-use-for-up-to-6-months-301481042.html
SOURCE Ascensia Diabetes Care
Copyright 2022 PR Newswire
1 Year Senseonics Chart |
1 Month Senseonics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions